Free Trial

Flossbach Von Storch SE Acquires Shares of 1,155 CME Group Inc. (NASDAQ:CME)

CME Group logo with Finance background

Flossbach Von Storch SE purchased a new stake in shares of CME Group Inc. (NASDAQ:CME - Free Report) during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,155 shares of the financial services provider's stock, valued at approximately $306,000.

A number of other institutional investors and hedge funds have also modified their holdings of the business. SeaCrest Wealth Management LLC grew its position in CME Group by 3.0% during the first quarter. SeaCrest Wealth Management LLC now owns 1,379 shares of the financial services provider's stock valued at $366,000 after purchasing an additional 40 shares in the last quarter. New Age Alpha Advisors LLC grew its stake in CME Group by 50.0% in the fourth quarter. New Age Alpha Advisors LLC now owns 129 shares of the financial services provider's stock valued at $30,000 after purchasing an additional 43 shares in the last quarter. Wealthcare Advisory Partners LLC grew its stake in CME Group by 3.6% in the first quarter. Wealthcare Advisory Partners LLC now owns 1,342 shares of the financial services provider's stock valued at $356,000 after purchasing an additional 47 shares in the last quarter. Koshinski Asset Management Inc. grew its stake in CME Group by 1.4% in the first quarter. Koshinski Asset Management Inc. now owns 3,522 shares of the financial services provider's stock valued at $934,000 after purchasing an additional 48 shares in the last quarter. Finally, Berry Wealth Group LP grew its stake in CME Group by 0.4% in the first quarter. Berry Wealth Group LP now owns 13,561 shares of the financial services provider's stock valued at $3,598,000 after purchasing an additional 49 shares in the last quarter. Hedge funds and other institutional investors own 87.75% of the company's stock.

Insider Activity at CME Group

In other news, Director Larry G. Gerdes sold 2,000 shares of the firm's stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $264.10, for a total transaction of $528,200.00. Following the completion of the transaction, the director directly owned 38,651 shares of the company's stock, valued at approximately $10,207,729.10. This trade represents a 4.92% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Derek Sammann sold 4,650 shares of the firm's stock in a transaction dated Monday, May 5th. The stock was sold at an average price of $280.61, for a total transaction of $1,304,836.50. Following the transaction, the insider directly owned 8,336 shares of the company's stock, valued at $2,339,164.96. The trade was a 35.81% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 13,400 shares of company stock worth $3,680,610 in the last ninety days. Company insiders own 0.30% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have commented on CME. Keefe, Bruyette & Woods boosted their target price on CME Group from $265.00 to $273.00 and gave the company a "market perform" rating in a research note on Thursday, April 24th. Citigroup boosted their target price on shares of CME Group from $265.00 to $275.00 and gave the stock a "neutral" rating in a research report on Thursday, July 3rd. JPMorgan Chase & Co. decreased their target price on shares of CME Group from $223.00 to $211.00 and set an "underweight" rating for the company in a research report on Thursday, April 24th. Bank of America boosted their target price on shares of CME Group from $200.00 to $219.00 and gave the stock an "underperform" rating in a research report on Wednesday, April 2nd. Finally, Oppenheimer boosted their target price on shares of CME Group from $282.00 to $300.00 and gave the stock an "outperform" rating in a research report on Wednesday, June 4th. Three analysts have rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. According to data from MarketBeat, CME Group has an average rating of "Hold" and a consensus target price of $260.93.

Read Our Latest Stock Analysis on CME Group

CME Group Stock Performance

CME Group stock traded down $0.45 during mid-day trading on Thursday, reaching $275.19. The company had a trading volume of 1,602,078 shares, compared to its average volume of 2,197,116. The company has a quick ratio of 1.02, a current ratio of 1.02 and a debt-to-equity ratio of 0.13. CME Group Inc. has a 52 week low of $193.17 and a 52 week high of $290.79. The company has a 50 day moving average of $276.69 and a 200-day moving average of $258.98. The firm has a market cap of $99.17 billion, a price-to-earnings ratio of 27.69, a PEG ratio of 3.74 and a beta of 0.44.

CME Group (NASDAQ:CME - Get Free Report) last announced its quarterly earnings data on Wednesday, April 23rd. The financial services provider reported $2.80 EPS for the quarter, topping analysts' consensus estimates of $2.61 by $0.19. CME Group had a return on equity of 14.03% and a net margin of 57.71%. The company had revenue of $1.64 billion during the quarter, compared to the consensus estimate of $1.56 billion. During the same quarter last year, the company earned $2.50 EPS. The company's quarterly revenue was up 10.4% on a year-over-year basis. On average, sell-side analysts expect that CME Group Inc. will post 10.49 EPS for the current fiscal year.

CME Group Dividend Announcement

The firm also recently disclosed a quarterly dividend, which was paid on Wednesday, June 25th. Stockholders of record on Monday, June 9th were issued a dividend of $1.25 per share. This represents a $5.00 dividend on an annualized basis and a dividend yield of 1.82%. The ex-dividend date was Monday, June 9th. CME Group's payout ratio is 50.30%.

About CME Group

(Free Report)

CME Group Inc, together with its subsidiaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers futures and options products based on interest rates, equity indexes, foreign exchange, agricultural commodities, energy, and metals, as well as fixed income and foreign currency trading services.

Featured Stories

Institutional Ownership by Quarter for CME Group (NASDAQ:CME)

Should You Invest $1,000 in CME Group Right Now?

Before you consider CME Group, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CME Group wasn't on the list.

While CME Group currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Don’t Miss These Top 3 Defense Stocks Set To Gain
Triple-Digit Gains: These 4 Nuclear Stocks Have Even More Upside Ahead
3 Made in America Stocks Under $20 You Need to See!

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines